Cannabis Law Report

AUGUST 12, 2022

. – August 11, 2022) – MOTAGON, a pharmaceutical company based in Prague and specializing in medical cannabis, has secured a ground-breaking agreement with Europe’s biggest indoor cannabis producer and one of the first cannabis extracts and formulations producers PHCANN INTERNATIONAL. ”

Extraction 52

Extraction Pharmaceutical Patients THC 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

FEBRUARY 1, 2022

New softgel capsule products further expand ZYUS’ medical cannabinoid offerings and provide patients a precise method for dosing. The launch of these two new softgel products marks another important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential.

Cannabinoids 52

Cannabinoids Patients Research and Development Media 52

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

NOVEMBER 17, 2021

Launch of Zylem ™ 20:1 further expands ZYUS product offerings with new cannabinoid formulation. The launch of this formulation marks an important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential. About ZYUS Life Sciences Inc. Visit www.zyus.com.

Cannabinoids 52

Cannabinoids Patients Research and Development Extraction 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

SpeedWeed

AUGUST 8, 2021

It’s the first cannabis-derived pharmaceutical to be legalized in many countries around the world, including the UK, Spain, United States, Canada, and New Zealand. . If all goes according to plan, patients will receive Sativex and the temozolomide chemotherapy drug, temozolomide on its own, or a placebo. View original article.

Cannabinoids 64

Cannabinoids Pharmaceutical DEA Medicine 64

United Patients Group

FEBRUARY 7, 2023

The effects of cannabis are caused by cannabinoids, which are chemical compounds found in the resin glands on the leaves and buds of female marijuana plants. Cannabinoids can help with inflammation and pain relief in various ways. Cannabis contains two types of cannabinoids: phytocannabinoids and endocannabinoids.

Cannabinoids 114

Cannabinoids Chronic Pain Terpenes THC 114

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Life Network

MAY 5, 2019

The acquisition brings together Canopy Growth‘s medical business with Europe’s largest cannabinoid-based pharmaceuticals company. C3 is a leading manufacturer and distributor of dronabinol, a registered pharmaceutical drug in Germany, Austria, Switzerland, and Denmark.

Cannabinoids 44

Cannabinoids Pharmaceutical Patients Business 44

Leafwell

JANUARY 15, 2021

This article is for medical marijuana patients and physicians alike. We believe knowledge is power and Leafwell seeks to educate not only patients but medical professionals as well.

Pharmaceutical 117

Pharmaceutical Education Cannabinoids Patients 117

Leafwell

JANUARY 15, 2021

This article is for medical marijuana patients and physicians alike. We believe knowledge is power and Leafwell seeks to educate not only patients but medical professionals as well.

Pharmaceutical 117

Pharmaceutical Education Cannabinoids Patients 117

Cannabis Law Report

JUNE 1, 2022

Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients. Our team in Europe is excited to join forces with new colleagues from Pharmadrug GmbH, with their valuable expertise in the German pharmaceutical market.”

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Canna Care Docs

OCTOBER 3, 2023

On top of overwhelming struggles or feelings, patients who have been diagnosed with a terminal illness can face a broad range of both physical and psychological effects. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Greencamp

MAY 1, 2019

Since then, countless patients found relief in cannabis, even though most of the times doctors would only recommend it when all other “mainstream” options were exhausted. However, some people don’t react well to antiemetics—most notably cancer patients going through aggressive chemo. And that’s where cannabis comes into play.

Patients 89

Patients Strains Sativa Marijuana 89

The Cannigma

JUNE 2, 2022

Ever wondered how cannabinoids like THC or CBD affect your blood? It turns out that this issue has been under-researched and could have significant impacts on patients who may be at greater risk of heart attacks and strokes. The short answer is – no, in most cases cannabinoids do not seem to act as strong blood thinners.

Blood Pressure 112

Blood Pressure Cannabinoids Patients THC 112

United Patients Group

MAY 17, 2023

Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention. Cannabinoids have been shown to help people with autism manage anxiety and stress.

Sleep 78

Sleep Cannabinoids Patients CBD 78

Canna Care Docs

JUNE 22, 2018

An Introductory Lesson on THC Basics For Medical Cannabis Patients. Cannabis, a plant that has proven to be endlessly complex is still under the microscope by researchers, patients, physicians, and society. But many new patients need an introduction on THC basics, learning how it plays a role in a patient’s well-being and healing.

THC 66

THC Patients Blood Pressure Clinical Trials 66

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

FloridaMarijuana.net

AUGUST 15, 2018

Most commonly, patients report that tingling and numbness occur, usually in the hands and feet. The endocannabinoid system consists of cannabinoid receptors all over the body. The compounds THC (tetrahydrocannabinol) and CBD (cannabidiol) found in cannabis signal the same cannabinoid receptors as anandamide.

Chronic Pain 150

Chronic Pain Marijuana Patients Clinical Trials 150

Veriheal

JANUARY 26, 2023

Most commonly, pharmaceutical medication is prescribed to regulate moods. However, pharmaceutical medications can have side effects, and they may take longer to work for many patients. Thus, this groundbreaking study laid the foundation for understanding how cannabinoids can support mental health.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JUNE 7, 2021

The Phase 1 clinical trial on Alzheimer’s patients is currently anticipated to conclude during the July through September 2021 timeframe. A Phase 1 clinical trial is the first step of a human clinical trial in a multi-step process designed to obtain regulatory approval for the marketing of a new pharmaceutical drug.

Clinical Trials 105

Clinical Trials Patients THC Safety 105

FloridaMarijuana.net

JUNE 22, 2018

Patients who suffer from this condition also face other symptoms that are painful, inconvenient -to say the least, -and lower their quality of life. An article published on the marijuanadoctor.com website discusses the best strains of marijuana for patients with IBS.

Hybrid 189

Hybrid Marijuana Sativa Nerve Pain 189

Cannabis Law Report

AUGUST 17, 2021

SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, announced the publication of a manuscript in the Journal of Pharmaceutical Sciences. About Receptor Life Sciences.

CBD 98

CBD Research and Development Pharmaceutical Therapy 98

Cannabis Law Report

AUGUST 29, 2021

This export also validates the emergence of the global cannabinoid sector with reliance on quality, traceability and sustainability that Avicanna ’s Aureus products offer. To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

Extraction 98

Extraction Supply Chain Research and Development CBD 98

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

United Patients Group

FEBRUARY 2, 2023

It’s made up of endocannabinoids and cannabinoid receptors, which work together to maintain homeostasis in the body by regulating things like mood, energy, appetite and sleep cycles. It does this by producing cannabinoids –chemical compounds that act on specific receptors throughout your body (1). antibiotics).

Blood Pressure 103

Blood Pressure Sleep Chronic Pain Digestion 103

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. More Than 1,000 PD Patients Surveyed.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

DECEMBER 14, 2021

Pharmaceutical giant Pfizer Inc. billion acquisition of Arena Pharmaceuticals, Inc. Arena Pharmaceuticals, based in San Diego, Cal., is a biotech company with one segment of its drug pipeline dedicated to cannabinoid-type therapeutics. is entering the cannabis space via the $6.7 Read more at.

Research and Development 52

Research and Development Pharmaceutical Therapy Treatment 52

Cannabis Law Report

DECEMBER 22, 2021

With growing interest in sustainable and bio-based cannabinoids, and after completing a strategic review of Hyasynth including their intellectual property (IP) and R&D platforms, Organigram remains excited about Hyasynth’s future and growth plans. million of secured convertible debentures in Hyasynth (the “Debentures”).

Cannabinoids 52

Cannabinoids Research and Development Events Pharmaceutical 52

MMJ Recs

JANUARY 6, 2024

In recent years, the landscape of medical marijuana has evolved dramatically, offering patients a diverse array of products tailored to address a myriad of health conditions. Capsules and pills provide a familiar oral ingestion method, akin to traditional pharmaceuticals.

Chronic Pain 52

Chronic Pain Topical Marijuana Indica 52

FloridaMarijuana.net

JULY 6, 2018

As the rate of cancer diagnoses rises worldwide, patients are finding more options with their treatments and healthcare routines. Patients can suffer from the disease itself, or from the side effects of chemotherapy and other pharmaceuticals medications. This epidemic affects not only patients, but their families and caregivers.

Strains 189

Strains Indica Nerve Pain Hybrid 189

Cannabis Law Report

JULY 29, 2021

With Avicanna’s dedication to quality standards and pharmaceutical positioning we are poised to be a significant long-term player in the European medical market that is predominantly focused on medical utility of cannabinoids and where meeting EU pharmacopeia standards are essential.”.

Extraction 98

Extraction Supply Chain THC Research and Development 98

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Whether used alone or in combination with other cannabinoids, CBD has shown promise in addressing a wide range of health concerns.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

OCTOBER 13, 2020

Elevated levels of stress can even land these individuals in more discomfort, with IBD patients risking hospitalization due to inflammation. Factors such as diet and stress are known to aggravate IBD patients, but they do not cause it. . What is IBS? What is the Difference Between IBD and IBS?

Digestion 123

Digestion Treatment Conditions Research and Development 123